MGIA
TXMD icon

Moneta Group Investment Advisors’s TherapeuticsMD TXMD Stock Holding History

Moneta Group Investment Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6
Closed -$6K – 503
2022
Q1 		$6K Sell
6
-275
-98% -$4.33K ﹤0.01% 446
2021
Q4 		$5K Sell
281
-16
-5% -$479 ﹤0.01% 475
2021
Q3 		$11K Sell
297
-6
-2% -$266 ﹤0.01% 453
2021
Q2 		$18K Buy
303
+4
+1% +$242 ﹤0.01% 447
2021
Q1 		$20K Buy
+299
New +$23.4K ﹤0.01% 418

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Moneta Group Investment Advisors's TXMD Position: Q2 2022 in Review

Moneta Group Investment Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 6 shares — an estimated $6K sold.

Moneta Group Investment Advisors first reported a position in TXMD in Q1 2021 and held it in 5 quarters. The position peaked at $20K in Q1 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Moneta Group Investment Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Moneta Group Investment Advisors sold 6 TherapeuticsMD shares in Q2 2022, an estimated $6K.
  • Moneta Group Investment Advisors first reported a position in TherapeuticsMD in Q1 2021 and held it in 5 quarters.
  • Moneta Group Investment Advisors's TherapeuticsMD position peaked at $20K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Moneta Group Investment Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.